Posts by:
Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing.
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001 Morassa Mohseni, Ben Ho Park J Clin Invest. 2010;120(8):2655-2658. https://doi.org/10.1172/JCI44026.
This case study reviews the use of olacitinib to treat cutaneous epitheliotropic T-cell lymphoma (CETL).
The “Median Isn’t the Message” is an essay written by Stephen J. Gould in 1991 as part of his book Bully for Brontosaurus: Reflections in Natural History. The essay has been reprinted many times for many different audiences. In 2013 it was reprinted in the American Medical Association Journal of Ethics. I believe that Stephen J. Gould’s message is as relevant today as it was when he originally wrote it. I thought this essay so important and so well written, that it was required reading for every one of my residents over the past 20 years.
On Thursday June 10th at 3pm EST/12pm PST, we were delighted to welcome Dr. Liz Pluhar to our webinar series.
Dr. Pluhar is a full professor and small animal surgeon in the Department of Veterinary Clinical Sciences at the University of Minnesota and leads the Canine Brain Tumor Clinical Trials Program.
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. By Laura Marconato, et al(Cancers (Basel). 2020 May 18;12(5):1272. doi: 10.3390/cancers12051272).
Dr. Elizabeth Iorns is a scientist whose research focuses on identifying mechanisms of breast cancer progression. She is a cofounder and CEO of Science Exchange, and she helped launch the Reproducibility Initiative. She was involved in the development of Olaparib, a targeted therapy directed at the BRCA1 and BRCA2 mutation, best known for its relation to breast cancer (and recently added to the FidoCure® platform).
The following medical brief espouses how ordinary clinical trial design is rendered less than perfect for targeted therapies, and suggests how the following 3 interrelated Agile Trial Design principles should be considered:
With new research and medical advancements, immunotherapy is the new frontier in veterinary oncology.
Please join us in welcoming Dr. Nicola Mason, B.Vet.Med,...
In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.
